Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 124

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 124
---
 the selling securityholders may arrange for other broker-dealers to participate in sales. If the selling securityholders effect such transactions by selling notes or note conversion ADSs to or through broker-dealers or agents, such broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling securityholders or commissions from purchasers of the notes for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus supplement, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 5110; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.

The notes are listed on the Official List of the Exchange under the symbol “IMMUNO30.” The Exchange is not a regulated market for the purposes of The Markets in Financial Instruments Directive (2004/39/EC). There is currently no established trading market for the notes in the United States and we do not expect a market to develop. We do not intend to list the notes on the Nasdaq Global Select Market or any other national securities exchange or any other nationally recognized trading system in the United States.

<div align='center'>S-68</div>

#### TABLE OF CONTENTS

### LEGAL MATTERS
The validity of the notes being offered by this prospectus supplement and certain other matters of U.S. federal law will be passed upon for us by Cooley LLP, New York, NY. Certain other matters of English law will be passed upon for us by Cooley (UK) LLP.

### EXPERTS
The financial statements of Immunocore Holdings plc as of December 31, 2024 and 2023, and for each of the two years in the period ended December 31, 2024, incorporated by reference in this prospectus supplement, and the effectiveness of Immunocore Holdings plc’s internal control over financial reporting have been audited by Deloitte LLP, an independent registered public accounting firm, as stated in their reports. Such financial statements are incorporated by reference in reliance upon the reports of such firm given their authority as experts in accounting and auditing.

The consolidated financial statements of Immunocore Holdings plc and subsidiaries as of December 31, 2022, and for the year ended December 31, 2022, have been incorporated by reference herein and in the registration statement in reliance